U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617597) titled 'Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata' on May 22.
Brief Summary: This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Alopecia Areata
Intervention:
DRUG: Deuruxolitinib
Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg
DRUG: Placebo
Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks
Recrui...